FRANKFURT, Germany , Nov. 20, 2024 /PRNewswire/ -- CABIO, a high-tech enterprise underpinned by biotechnology and listed on the Science and Technology Innovation Board (stock code: 688089), unveiled its innovative product, NeoHMOs®, at the Food Ingredients Europe event held in Frankfurt, Germany . Recently, CABIO's Human Nutrition Business Unit has made frequent appearances in international exhibitions, participating in events such as SupplySide West in Las Vegas , USA , and Food Ingredients Europe.
These participations have facilitated discussions on future industry trends and cooperation with global partners. At the Food Ingredients Europe event, CABIO presented its latest product, NeoHMOs®, which has obtained approval in China and adheres to all European Union standards. Through cutting-edge technology, CABIO has improved the flavor and flow characteristics of 2'-FL powder, simplifying its incorporation into various products and providing scientifically validated and safe nutritional support for infant development.
Furthermore, CABIO demonstrates a strong commitment to environmental sustainability by utilizing renewable raw materials for large-scale manufacturing, thereby reducing land and natural resource consumption while offering sustainable health and nutrition solutions on a global scale. As Human Milk Oligosaccharides (HMOs) continue to gain prominence worldwide, this achievement represents a significant milestone in CABIO's application of synthetic biology in indu.
